# NCT03836209 (NCT03836209)

> Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03836209
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: PrECOG, LLC.
- Conditions: Acute Myeloid Leukemia
- Interventions: Gilteritinib; Midostaurin; Daunorubicin; Cytarabine
- Enrollment: 181
- Primary outcome: FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 6
- X threads: 5
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03836209

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03836209", "email": "<work email>"}; the inbox owner confirms by the emailed link.